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study was to evaluate these PQA measures and assess predictors of qualifying into 
these measures among Medicaid beneficiaries from 39 states in the US. Methods: 
Medicaid beneficiaries from 39 US states aged 5 to 50 years were identified in cal-
endar year 2008. Of these, beneficiaries who filled one or more prescriptions for 
COPD medications, dornase alfa, or nasal steroid medications were excluded from 
the analysis. Beneficiaries with at least three canisters of short-acting beta agonists 
within 90 days were identified as those with SAC. Of the beneficiaries with SAC, 
those who did not receive asthma controller therapy in the same 90 day period 
were identified as those with ACT. Predictors of SAC and ACT were identified in 
2007. Results: A total of 77,783 asthma patients were identified in 2008. On an 
average, the proportion of patients with SAC and ACT in each state was 36.51% and 
54.15% respectively. Higher age (OR:1.023; CI:1.022-1.024), male gender (OR:1.205; 
CI:1.180-1.230), Caucasian (OR:0.889; CI:0.873-0.906) and African American race 
(OR:0.799; CI:0.772-0.826), greater number of hospital visits (OR:1.034; CI:1.025-
1.042), and greater number of asthma-related office visits (OR:1.194; CI:1.185-1.204) 
were significant predictors of SAC. Lower age (OR:0.996; CI:0.995-0.998), male gender 
(OR:1.121; CI:1.085-1.159), Caucasian (OR:1.279; CI:1.241-1.319) and African American 
race (OR:1.067; CI:1.009-1.128), greater number of emergency room visits (OR:1.021; 
CI:1.017-1.026), and lower number of asthma-related office visits (OR:0.696; CI:0.686-
0.706) were significantly associated with ACT. ConClusions: Patient demographics 
and resource utilization in the previous year are significant predictors of SAC and 
ACT. Prescribers and payers should use these to identify patients with persistent 
asthma most likely to misuse SABA and who need more appropriate use of asthma 
controller therapy.
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objeCtives: Allergic rhinitis (AR) affects 10-20% of the US population, with treat-
ment costs exceeding $6 billion annually. US practice guidelines suggest treatment 
with a combination of intranasal corticosteroids and antihistamines. MP29-02 is 
intranasal formulation of azelastine hydrochloride and fluticasone propionate in 
an advanced delivery system indicated for the relief of symptoms of seasonal AR 
(SAR). Patients treated with MP29-02 experience significantly greater symptom 
relief in comparison to first-line therapy in trials. OBJECTIVE: To use an economic 
model to calculate the per-member per-month (PMPM) budget impact on a US 
health insurer of moving MP29-02 from third-tier to second-tier pricing and reim-
bursement. Methods: Population is SAR sufferers seeking treatment. MP29-02 
is assumed to gain market share annually with second-tier pricing. Time horizon 
is one year and five years. Perspective is a US health plan with 500,000 enroll-
ees. BIA is a pharmacy cost impact model using data from literature and supplied 
by Meda. Model assumes 10% branded drug price inflation; 80% brand to generic 
share shift and 50% price reduction; tiered payer rebate percentages and patient 
copay amounts. Results: Estimated treated SAR population ranged from 63,165 at 
baseline to 68,630 in Year 5. Branded share of fluticasone-based products declined 
from 17% to 7%. Overall SAR treatment budget declined from $3.2 million annu-
ally at baseline to $3.1 million in Year 5 reflecting expected shift from branded to 
generic market share. According to baseline assumptions, marginal change in costs 
over the one-year time horizon from moving MP29-02 from third-tier to second-
tier pricing are $19,659 (< $0.01 PMPM). Costs associated with the 5-year horizon, 
given changes in market shares, are $97,342 ($0.01 PMPM). ConClusions: MP29-02 
offers an appropriate means of adhering to AR practice guidelines and improving 
outcomes, and this BIA model shows that the added costs of those benefits are 
minimal to US payers.
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objeCtives: Respiratory syncytial virus (RSV) is a primary cause of lower respir-
atory tract infection in infants and children and leads to substantial morbidity. 
Palivizumab is a monoclonal antibody demonstrated to significantly reduce the 
frequency of hospitalizations for RSV infection in high-risk populations, including 
preterm infants and children with bronchopulmonary dysplasia and congenital 
heart disease. National costs of implementing a childhood prophylaxis program 
have not been well characterized. The objective was to compare the financial impact 
of implementing a RSV prevention program in high-risk infants using palivizumab, 
to three established childhood prophylaxis programs in Mexico: 13-valent pneu-
mococcal conjugate vaccine (PCV13); quadrivalent human papillomavirus (HPV) 
vaccine; and Bordetella pertussis (B. pertussis) vaccine. Methods: A model was 
developed to estimate the one-year budget impact of palivizumab for the preven-
tion of severe RSV infection in high-risk populations in Mexico, from the national 
health care perspective. Model inputs were derived following a literature review on 
the health care system, and included the epidemiology of severe RSV infection in 
Mexico and Latin America, with appropriate Mexican resource utilization and cost 
estimates. Results: The cost of prophylaxis with palivizumab was approximately 
MXN$283 million. The corresponding costs for PCV13, HPV vaccine, and B. pertus-
sis vaccine were estimated at MXN$1.1 billion; MXN$579 million; and MXN$636 
million, respectively. Total disease cost estimates were MXN$878 million for RSV 
found in their countries of origin. A longer stay in the host country or being a child 
of immigrant parents is associated with increasing adaption to the new environ-
ment, and therefore the prevalence of asthma and allergies over time converge 
with the prevalence in the non-immigrant host population. Comparisons between 
populations in their countries of origin and those that emigrated vary depending on 
their level of development; more developed countries show higher rates of asthma 
and allergies. ConClusions: Preliminary findings suggest a strong influence of 
the environment on the development of asthma and allergies. The prevalence of 
asthma is generally higher in second generation immigrants. With length of stay 
the prevalence of asthma and allergies increases steadily. Further analysis should 
assess homogeneity across studies and obtain pooled risk estimates of migration 
status as a risk factor for asthma and allergies.
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objeCtives: Tobacco use remains the leading preventable cause of premature 
death worldwide. Survey-based smoking related data has been collected from China, 
Jordan, India, Taiwan, and Saudi Arabia between 2009-2012. Predictors of smoking 
within each country have been identified and recently published. The objective was 
to identify and compare smoking predictors that remain significant across coun-
tries after combining the data from various countries into one dataset. Methods: 
Survey questions included socio-demographic characteristics, history of tobacco 
smoking, and environmental determinants of smoking like family and peer tobacco 
use. Multivariate logistic regression was constructed to determine predictors of 
smoking in the past month vs. no smoking. Results: A total of 3,658 adults par-
ticipated in the survey. Forty four percent of the participants had smoked cigarettes 
in the past month. Females were less likely to smoke (OR= 0.30, 95% CI= 0.22-0.42), 
whereas adults older than 25 (OR= 1.63, 95% CI= 1.16-2.29) or working/studying 
in medical related field (OR= 2.08, 95% CI= 1.10-3.95) were more likely to smoke. 
Compared to China participants, those from India, Saudi Arabia, Taiwan were less 
likely to smoke (OR= 0.13, 95% CI= 0.06-0.27 for India, OR= 0.005, 95% CI= < .001-0.07 
for Saudi Arabia, and OR= 0.04, 95% CI= 0.002-0.94 for Taiwan) while no significant 
differences were observed with Jordan participants. Teachers’ anti-smoking mes-
sages significantly decreased the likelihood of smoking (OR= 0.35, 95% CI= 0.13-0.90). 
Social network, on the other hand, significantly increased the likelihood of smoking, 
especially among siblings (OR= 1.70, 95% CI= 1.25-2.31) and close friends (OR= 1.96, 
95% CI= 1.34-2.86). Other variables associated with smoking included experiences 
with dyspepsia, education level, grades, personal feelings in previous week, and 
other substance use experiences (alcohol/cigar/chewing tobacco). ConClusions: 
The high smoking prevalence observed documents the magnitude of problem across 
these five countries. Future research should aim to incorporate the predictors identi-
fied above to develop effective interventions.
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objeCtives: Clinical trials have demonstrated that daily LAMA therapy in patients 
with COPD can improve lung function and quality of life. When LAMAs are clini-
cally indicated, the three oral agents currently available include tiotropium bro-
mide (TIOB), glycopyrronium (GLYCO) and most recently aclidinium bromide (ACLB). 
Placebo controlled trials have demonstrated efficacy, but safety data from head to 
head comparative trials are limited. In the absence of such data, mixed treatment 
comparison (MTC) models are a widely accepted statistical method of generating 
comparative safety information on clinically relevant but rare adverse events. In 
this study, an indirect comparison on safety was undertaken between TIOB, GLYCO 
and ACLB. Methods: A systematic literature review of major English language 
databases was conducted from January 1992 to December 2013 for randomized pla-
cebo controlled trials evaluating at least one of the three agents in COPD. Bayesian 
MTC models were fitted to assess comparative safety based on major adverse 
cardiovascular events (MACE), acute urinary retention (AUR), glaucoma and all-
cause mortality. Outcomes were adjusted for treatment duration and presented 
as a relative risk (RR) against ACLB. Results: A total of 20 randomized trials met 
the inclusion criteria. Insufficient trial data were reported to allow an evaluation 
of AUR and glaucoma. There were no significant differences in the risk of MACE 
between TIOB vs. ACLB (RR= 1.11; 95%CrI: 0.14 to 11.5) as well as GLYCO vs. ACLB 
(RR= 3.5; 95%CrI: 0.34 to 52.7). Similarly, there were no significant differences in the 
risk of all-cause mortality between TIOB (1.11; 95%CrI: 0.16 to 7.7) and GLYCO (0.84; 
95%CrI: 0.08 to 8.3) relative to ACLB. However, the magnitude of the RR for MACE 
suggests the potential for an increased risk with GLYCO when used as an alterna-
tive to ACLB. ConClusions: The risk of MACE and all-cause mortality with ACLB 
is comparable to both TIOB and GLYCO in patients with COPD.
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objeCtives: The ‘suboptimal asthma control’ (SAC) and the ‘absence of controller 
therapy’ (ACT) measures endorsed by the Pharmacy Quality Alliance evaluate inap-
propriate medication taking behavior in patients with asthma. The purpose of this 
